Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 5Not yet recruiting 3Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1

Conditions

TP53 Y220C Mutation 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Leiomyosarcoma 1

Interventions

Specimen Handling 481pembrolizumab 454Magnetic Resonance Spectroscopy 419Carboplatin 321Cyclophosphamide 314Biopsy 272Cisplatin 264Radiotherapy 239Paclitaxel 226Gemcitabine 222Bevacizumab 212Nivolumab 189fludarabine 183venetoclax 172Drug Therapy 165Dexamethasone 157Blood Specimen Collection 156Oxaliplatin 154Injections 152Capecitabine 152Fluorouracil 144Docetaxel 142Standard of Care 136Radiosurgery 136Rituximab 125Pemetrexed 115durvalumab 113atezolizumab 110Leucovorin 110Radiation 105

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Rosuvastatin Calcium × 1 year × Clear all
NCT07372625 2026-03-12

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

PMV Pharmaceuticals, Inc

Phase 1 Recruiting
14 enrolled
Other solid neoplasm

TP53 Y220C Mutation

NCT03016819 2026-02-25

APROMISS

Advenchen Laboratories, LLC

Phase 3 Recruiting
325 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡